Exploiting the p53 pathway for cancer diagnosis and therapy

British Journal of Cancer

Volumn 80, Issue SUPPL. 1, 1999, Pages 1-5

  Lane, D P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; GENES, P53; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032813181     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690312     Document Type: Conference Paper

References (25)

1. Barak Y, Juven T, Haffner R and Oren M (1993) Mdm2 expression is induced by wild-type p53 activity. Embo J 12: 461-468
2. Bartek J, Bartkova J, Vojtesck B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV and Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703
3. Blaydes JP, Gire V, Rowson JM, Wynford Thomas D (1997) Tolerance of high levels of wild type p53 in transformed epithelial cells dependant on auto regulation by Mdm2, Oncogene 14: 1859-1868.
4. Bottger V, Bottger A, Howard SF, Picksley SM, Chene P, Garcia-Echeverria C, Hochkeppel HK and Lane DP (1996) Identification of novel Mdm2 binding peptides by phage display. Oncogene 13: 2141-2147
5. Bottger A, Bottger V, Garcia-Echeverria C, Chene P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM and Lane DP (1997a) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269; 744-756
6. Bottger A, Bottger V, Sparks. A, Liu WL, Howard SF and Lane DP (1997b) Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo, Curr Biol 7: 860-869
7. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799
8. Hall PA, McKee PH, Menage HD, Dover R and Lane DP (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8: 203-207
9. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
10. Hupp TR, Sparks A and Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-245
11. Kubbutat MH, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303
12. Lane DP (1992) Cancer. p53, guardian of the genome, Nuture 358; 15-16
13. Lane DP and Hall PA (1997) Mdm2; arbiter of p53's destruction. Trends Biochem Sci 22: 372-374
14. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
15. Lu X and Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75: 765-778
16. Lutzker SG and Levine AJ (1990) A functionally inactive p53 protein in teralocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 2: 804-810
17. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, Walsh FS, Wright EG, Balmain A, Lane DP and Hall PA (1996) The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13: 2575-2587
18. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP and Hall PA (1994) The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617
19. Midgley CA and Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189
20. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D and Barnes DM (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 101: 183-189
21. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The Mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
22. Picksley SM, Vojtesek B, Sparks A and Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2 - fine mapping of the Mdm2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529
23. Sharpless NE and De Pinho RA (1999) The Ink4A/ARF locus and its gene products. Curr Opin Genet Dev 9: 22-30
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
25. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC and Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632-638